pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$AXSMAxsome Therapeutics, Inc.

$AXSM137.01-3.30%
New York, NY, USupdated 18h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
3
phase 3
1
catalysts ytd
5
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 3: 1Marketed: 3Unknown: 1
1Phase 33Marketed1Unknown
Marketed
(bupropion hydrochloride + dextromethorphan) ER
Dementia Associated With Alzheimer's Disease
Marketed
(meloxicam + rizatriptan benzoate)
Migraine
Marketed
solriamfetol hydrochloride
Obstructive Sleep Apnea
Phase 3
reboxetine
Type 1 Narcolepsy (Narcolepsy with Cataplexy)
drug
AUVELITY
1 INDICATIONS AND USAGE AUVELITY is indicated for the tre…
Sodium-dependent dopamine transporterSodium-dependent noradrenaline transporter

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 2, 2026
earnings
$AXSM137.01-3.30%
15d ago
Axsome Therapeutics, Inc. earnings
Axsome Therapeutics, Inc.
→
view all catalysts →

Active trials

  • phase3An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHDenrolling by invitationn=300
  • phase3Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgiaenrolling by invitationn=300
  • phase3Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)recruitingn=468
  • —SUNOSI® (Solriamfetol) Pregnancy Registryrecruitingn=1,731
  • phase3A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitationcompletedn=408
  • phase3Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Designrecruitingn=620
  • phase2Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)completedn=21
  • phase3Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetolrecruitingn=508
🐶 Hiring Signal
No open roles indexed yet — view Axsome Therapeutics, Inc. jobs →

News

  • Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
    Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…
    biopharma_dive · 6mo ago
identifiers
ticker
$AXSM
SEC CIK
0001579428
country
US
source
sec_tickers
top tags
Major Depression1Pulmonology1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 21m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?